Today we announced that the U.S. Food and Drug Administration has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee supporting mFLUSIVA for adults 50 years of age and older. Read more: https://lnkd.in/gJvvNnUp
Moderna
Biotechnology Research
Cambridge, Massachusetts 797,408 followers
Our mission is to deliver the greatest possible impact to people through mRNA medicines.
About us
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762). Please be cautious of fraudulent recruitment offers claiming to be from Moderna. Recruitment scams of this sort may originate from fake websites, social media accounts, or unsolicited communications and may ask you for personal information or request you pay them or someone else. Moderna will never ask you for payment, banking information, or anything of this sort at any stage of the recruitment process. If you are unsure about a communication, do not provide personal information and report the activity to recruitmentfraud@modernatx.com. You may also report suspected fraud to the FBI’s Internet Crime Complaint Center (IC3).
- Website
-
https://www.modernatx.com/?tc=soc_7y8qkt&cc=1004
External link for Moderna
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2010
- Specialties
- Biotechnology and mRNA Therapeutics
Locations
-
Primary
Get directions
200 Technology Sq
Cambridge, Massachusetts 02139, US
-
Get directions
1 Upland Rd
Norwood, Massachusetts 02062, US
Employees at Moderna
Updates
-
Today we announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, our investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus disease. Read more: https://lnkd.in/g2AwTwsX
-
-
Today we reported financial results and provided business updates for the second quarter of 2026. Read more: https://lnkd.in/gFPakB8q
-
-
It was a pleasure to welcome Mélanie Joly and members of her team to our global headquarters in Cambridge, Massachusetts. We valued the opportunity to exchange perspectives and share more about the impact of our work in Canada and around the world. ----------------- Ce fut un plaisir d'accueillir Mélanie Joly et les membres de son équipe à notre siège mondial à Cambridge, Massachusetts. Nous avons apprécié l'occasion d'échanger des perspectives et de partager davantage sur l'impact de notre travail au Canada et dans le monde entier.
-
-
Today we announced the dosing of the first U.S. participant in our Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. Read more: https://lnkd.in/gnCDrmmd
-
-
At Moderna, our Mission is to deliver the greatest possible impact to people through mRNA medicines. In pursuit of this, we remain focused on advancing our science, supporting our people, and delivering for patients, communities, and the environment. Our latest Impacting Human Health Report reflects how we are continuing to turn scientific progress into meaningful impact while helping shape a healthier future for people around the world. Read the full report: https://lnkd.in/ggZ_DaCd
-
-
Today we announced the appointment of Michael McDonnell to our Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee. Read more: https://lnkd.in/g_C_j-XR
-
-
In honor of #PrideMonth, Moderna colleagues around the world came together to celebrate the LGBTQ+ community through employee-led events, local Pride celebrations, and opportunities to connect and learn. At Moderna, we believe our best work happens when people can bring their unique perspectives, know they have a voice, and feel that it matters. That's why we lead with belonging—building a culture where employees feel safe, valued and included. Through the efforts of the Moderna RaiNbow Alliance, our LGBTQ+ employee resource group, and colleagues globally, we continue to strengthen a sense of belonging across our organization. Happy Pride! 🌈❤️
-
-
Yesterday, Moderna announced research and early development updates at our Science Day event. Members of our executive team sat down to provide more insight into our strategy that balances near-term growth with long-term innovation. Watch our latest IR Insights video to learn more: https://lnkd.in/gjWHXjae
-